Zephyr® Valve has Broad Coverage
More than 90% of patients nationwide are under policies with positive coverage or under plans that are not restricting access.*
- Medicare is covering patients who qualify
- >95% of patients with commercial insurance are securing coverage**
*Pulmonx data on file; assuming patients meet medical criteria for BLVR.
Zephyr Valves are approved by the Food and Drug Administration (FDA). Providers should contact their individual payers prior to performing the Zephyr Valve procedure for information on coverage.
The information is subject to change without notice because of complex and frequently changing laws, regulations, rules, and policies.
For reimbursement information, please visit: bit.ly/4aipqRI.
**Pulmonx Patient Reimbursement Support Program experience through the prior authorization process, for cases where patients opted in.
International Guidance Documents Include Endobronchial Valve Treatment as an Option for Emphysema Patients
Multiple independent networks have concluded that with proper patient selection, endobronchial valves, such as Zephyr Valves, should be considered in the treatment of severe emphysema.
The quality of evidence for treatment with endobronchial valves has been graded “A” by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).10
The United Kingdom’s National Institute for Health and Care Excellence (NICE) has included this treatment as part of standard measures for COPD and recommended all qualifying patients be evaluated for eligibility.11,34
Published clinical evidence can be found by clicking the button below.
